BLFS BioLife Solutions Company Net Income

Official company branding of biolifesolutions.com (BLFS)

BioLife Solutions, Inc. (BLFS) operates in the critical cryopreservation niche, where it faces pressure from laboratory equipment behemoths and the risk of shifting storage technologies. The business relies on bioprocessing investment cycles, focusing on CryoStor sales and the success of CAR-T therapy. The current figure is 0.05. Serving as a valuation tool, this price-to-earnings chart confirms that the company has entered the margin scaling phase.

BLFS: BioLife Solutions, Inc. Net Profit 07/04/2022 - 10/18/2026

Financial and market metric breakdowns for BioLife Solutions (BLFS)

- current quotes and average value forecast:
Market Chart BioLife|BLFS - Price Target Chart
- market capitalization data:
Market Value BioLife|BLFS - Total Company Value
- balance sheet equity data:
Net Assets per Single Share BioLife Solutions|BLFS - Book Capitalization|Market Capitalization to Book Value biolifesolutions.com|BLFS - Company Total Assets
- debt and liquidity details:
Aggregate Debt to Equity BioLife Solutions, Inc.|BLFS - Long-Term Debt to Capital|Current Liabilities to Capital BioLife Solutions Inc|BLFS - Company Total Debt|Debt to Net Assets Ratio BioLife|BLFS - Company Long-Term Debt|Short-Term Debt Volume BioLife Solutions|Immediate Liquidity biolifesolutions.com
- earnings and valuation multiples information:
BLFS - Company Net Income
Summary company analysis:BioLife (BLFS)
Product sample of BioLife Solutions, Inc.

To objectively assess the operational efficiency of BioLife Solutions, Inc. (BLFS), investors must analyze the dynamics of real cash flow. This indicator measures the equity value of net profit for each operating day, as reflected in the company's annual earnings. Stable growth of the line confirms the business's fundamental ability to generate income. For BioLife Solutions, Inc. (BLFS), this trend is amplified by the scaling of high-margin CryoStor systems. However, a sharp spike in this metric may signal a risk of margin compression during a cycle shift.

Main competitors

TEM - Net Financial Result|Company Net Income Qiagen N.V.|Company Net Income ionispharma.com IONS|Company Net Income Repligen (RGEN)|Company Net Income RNA (Avidity Biosciences Inc)|Net Profit CRSP (CRISPR Therapeutics Corp)|Net Financial Result GeneDx Corp (WGS)|Ultragenyx Pharmaceutical - Net Profit|Profit After Tax BEAM|SRPT: Net Profit|Company Net Income Twist Bioscience Inc (TWST)|Net Income TXG|NTLA: Final Profit|Company Net Income Stoke Therapeutics (STOK)|Net Financial Result wavelifesciences.com|Company Net Income Maze Therapeutics MAZE|Sionna Therapeutics, Inc. (SION) - Company Net Income|PRME - Company Net Income|TSHA: Company Net Income|QURE (uniQure N.V.) - Net Income|meiragtx.com (MGTX) - Net Profit|Net Income RGNX|SLDB (Solid Biosciences Inc) - Profit After Payment of Taxes|Net Profit OCGN|Net Financial Result PacBio Corp|Company Net Income Benitec Biopharma Inc. BNTC|designtx.com (DSGN) - Company Net Income|RCKT - Company Net Income|FDMT (4DMT) - Company Profit|lexeotx.com (LXEO) - Company Net Income|KRRO - Net Financial Result|Net Income EDIT|SLN: Final Profit|Net Profit PRQR|Net Financial Result codexis.com|Company Net Income Sangamo SGMO|NAUT: Company Profit|Metagenomi, Inc. - Net Profit|Precision BioSciences Inc. (DTIL) - Net Income|GBIO (generationbio.com) - Net Income|BOLD - Net Financial Result|XCUR (Exicure Inc.) - Net Profit|Company Net Income IMNN|Company Net Income Phio Pharmaceuticals (PHIO)|Company Net Income MBIO (mustangbio.com)|Net Profit RNAZ (TransCode Therapeutics, Inc.)|BNGO (Bionano Genomics Inc.) - Profit After Tax|APDN - Company Net Income|Net Financial Result bluebird bio, Inc BLUE|IPA: Net Profit|Company Profit OMGA|Company Net Income Singular Genomics|Company Profit RGLS (Regulus Therapeutics, Inc.)|Net Profit SYRS|Net Profit Telesis Bio, Inc (TBIO)|Net Profit TCON (TRACON Pharmaceuticals)|unitybiotechnology.com - Company Net Income